SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
SPRUCE BIOSCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$40.40+0.75 (+1.89%)
Close on Oct 19, 2026
- Market cap
- $98.22M
- P/E (TTM)
- –
- Dividend yield
- –
SPRUCE BIOSCIENCES, INC. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -109.2%
Financial strength
- Current ratio
- 9.23
- Debt to equity
- 0.08
- Debt to assets
- 6.9%
- Cash to current liabilities
- 878.4%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.17
- Dividend yield
- –